Non-viral nanoparticles

CTS has developed a new non-viral particle approach to deliver gene products for patients. CTS’ particles are prepared as a freeze dried (lyophilized) preparation that can be rehydrated for intravenous administration. Particles distribute throughout the body and can be repeatedly administered over time, as required.

Technology

The consistent and reproducible manufacture of nanoparticles at scale, has been a challenge for the industry. CTS’s proprietary flash nano-complexation method produces highly defined particles with tuneable specifications and draws on world leading research, principally from Johns Hopkins University. This process uses a patented confined impinging jet mixing device that creates optimal conditions for efficient in-line complexation of nucleic acids with polymer thereby overcoming the inconsistencies of batch nanoparticle production methods. The resulting nanoparticles can be freeze dried for long term storage without loss of performance and then simply reconstituted with water prior to administration.

Pre-clinical proof of concept work has demonstrated the effectiveness of such particles for delivering a wide range of gene payloads, for the expression of proteins, to treat disease.

Board

Martin Pomper

Director

Co-scientific founder of CTS, practicing clinician and Professor of Radiology at Johns Hopkins University.

View profile

Will West

President & CEO

20 years’ experience of product discovery and development in biotech and pharma. BIA Board, BBSRC Council.

View profile

Jason R. Dinges

Director

Investor Director representing CTS’ main shareholder. Molecular biology background and qualified patent attorney.

View profile

Contact

Email: info@cts-bioscience.com
Telephone: +44 1799 531 130

Email us

UK operating address:
The Mansion,
Chesterford Research Park
Cambridge
CB10 1XL
UK

US registered address:
Cancer Targeting Systems, Inc.
1188 Centre Street
Newton Centre
Boston, MA 02459
USA

Non-viral nanoparticles

CTS has developed a new non-viral particle approach to deliver gene products for patients. CTS’ particles are prepared as a freeze dried (lyophilized) preparation that can be rehydrated for intravenous administration. Particles distribute throughout the body and can be repeatedly administered over time, as required.

Technology

The consistent and reproducible manufacture of nanoparticles at scale, has been a challenge for the industry. CTS’s proprietary flash nano-complexation method produces highly defined particles with tuneable specifications and draws on world leading research, principally from Johns Hopkins University. This process uses a patented confined impinging jet mixing device that creates optimal conditions for efficient in-line complexation of nucleic acids with polymer thereby overcoming the inconsistencies of batch nanoparticle production methods. The resulting nanoparticles can be freeze dried for long term storage without loss of performance and then simply reconstituted with water prior to administration.

Pre-clinical proof of concept work has demonstrated the effectiveness of such particles for delivering a wide range of gene payloads, for the expression of proteins, to treat disease.

Board

Martin Pomper

Director

Co-scientific founder of CTS, practicing clinician and Professor of Radiology at Johns Hopkins University.

View profile

Will West

President & CEO

20 years’ experience of product discovery and development in biotech and pharma. BIA Board, BBSRC Council.

View profile

Jason R. Dinges

Director

Investor Director representing CTS’ main shareholder. Molecular biology background and qualified patent attorney.

View profile

Contact

Email: info@cts-bioscience.com
Telephone: +44 1799 531 130

Email us

UK operating address:
The Mansion,
Chesterford Research Park
Cambridge
CB10 1XL
UK

US registered address:
Cancer Targeting Systems, Inc.
1188 Centre Street
Newton Centre
Boston, MA 02459
USA